Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Smoldering Multiple Myeloma 3Pancreatic Neoplasms 2Multiple Myeloma 2Melanoma 2Triple Negative Breast Neoplasms 1PTEN-Altered Advanced Solid Tumors and HER2 Negative Breast Cancer 1Neuroendocrine Tumors 1Neoplasms 1Neoplasm Metastasis 1Myasthenia Gravis 1Multiple Endocrine Neoplasia 1Lung Neoplasms 1Hematologic Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1Breast Diseases 1Arthritis, Rheumatoid 1Acute Graft Versus Host Disease 1

Interventions

Radiosurgery 79Capecitabine 77Oxaliplatin 74Fluorouracil 69Bevacizumab 69Gemcitabine 67Leucovorin 61pembrolizumab 53Nivolumab 53Paclitaxel 48Irinotecan 47Radiotherapy 45Cisplatin 44Everolimus 38Magnetic Resonance Spectroscopy 36Drug Therapy 36Docetaxel 36Cyclophosphamide 35Cetuximab 35Ipilimumab 32Carboplatin 32Trastuzumab 31Sunitinib 30Sorafenib 26Erlotinib Hydrochloride 25Doxorubicin 23Surveys and Questionnaires 20Surgical Procedures, Operative 20Specimen Handling 20Biopsy 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neoplasm Metastasis × Leflunomide × Clear all
NCT01611675 2017-04-06

Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma

Massachusetts General Hospital

Phase 1 Terminated
3 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡